These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35448196)

  • 21. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
    Bon G; Pizzuti L; Laquintana V; Loria R; Porru M; Marchiò C; Krasniqi E; Barba M; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Barchiesi G; Mazzotta M; Marinelli D; Tomao S; Marchetti P; Valerio MR; Mirabelli R; Russo A; Fabbri MA; D'Ostilio N; Veltri E; Corsi D; Garrone O; Paris I; Sarobba G; Giotta F; Garufi C; Cazzaniga M; Del Medico P; Roselli M; Sanguineti G; Sperduti I; Sapino A; De Maria R; Leonetti C; Di Leo A; Ciliberto G; Falcioni R; Vici P
    J Exp Clin Cancer Res; 2020 Dec; 39(1):279. PubMed ID: 33302999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.
    Hu S; Wu Y; Luan J; Wang S; Fan G
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17933-17942. PubMed ID: 37964082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer.
    Kınıkoğlu O; Odabas H; Altıntaş YE; Yıldız A; Çakan B; Akdağ G; Yıldırım S; Bal H; Kaya T; Tünbekici S; Işık D; Başoğlu T; Yıldırım ME; Turan N
    Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929568
    [No Abstract]   [Full Text] [Related]  

  • 25. Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer.
    Stanowicka-Grada M; Senkus E
    Curr Treat Options Oncol; 2023 Nov; 24(11):1633-1650. PubMed ID: 37878202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
    Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neratinib: an option for HER2-positive metastatic breast cancer.
    O'Shaughnessy JA; O'Regan R; Isaacs C
    Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Hurvitz SA; Hegg R; Chung WP; Im SA; Jacot W; Ganju V; Chiu JWY; Xu B; Hamilton E; Madhusudan S; Iwata H; Altintas S; Henning JW; Curigliano G; Perez-Garcia JM; Kim SB; Petry V; Huang CS; Li W; Frenel JS; Antolin S; Yeo W; Bianchini G; Loi S; Tsurutani J; Egorov A; Liu Y; Cathcart J; Ashfaque S; Cortés J
    Lancet; 2023 Jan; 401(10371):105-117. PubMed ID: 36495879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
    Lazaratos AM; Maritan SM; Quaiattini A; Darlix A; Ratosa I; Ferraro E; Griguolo G; Guarneri V; Pellerino A; Hofer S; Jacot W; Stemmler HJ; van den Broek MPH; Dobnikar N; Panet F; Lahijanian Z; Morikawa A; Seidman AD; Soffietti R; Panasci L; Petrecca K; Rose AAN; Bouganim N; Dankner M
    Breast; 2023 Jun; 69():451-468. PubMed ID: 37156650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021.
    McAndrew NP
    Curr Opin Obstet Gynecol; 2022 Feb; 34(1):41-45. PubMed ID: 34967814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
    Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
    J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
    Schettini F; Conte B; Buono G; De Placido P; Parola S; Griguolo G; Fabi A; Bighin C; Riccardi F; Cianniello D; De Laurentiis M; Puglisi F; Pelizzari G; Bonotto M; Russo S; Frassoldati A; Pazzola A; Montemurro F; Lambertini M; Guarneri V; Cognetti F; Locci M; Generali D; Conte P; De Placido S; Giuliano M; Arpino G; Del Mastro L
    ESMO Open; 2021 Apr; 6(2):100099. PubMed ID: 33819752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
    Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J
    Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
    Sanglier T; Shim J; Lamarre N; Peña-Murillo C; Antao V; Montemurro F
    Breast; 2023 Jun; 69():441-450. PubMed ID: 36709091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic advances in HER2+ breast cancer].
    Alexandre M; Jacot W
    Rev Prat; 2023 Apr; 73(4):355-359. PubMed ID: 37289145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients.
    Due A; Berg T; Jensen MB; Yammeni S; Volmer L; Brems-Eskildsen AS; Andersen KK; Rana S; Knoop A; Kümler I
    Acta Oncol; 2023 Feb; 62(2):126-133. PubMed ID: 36929759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot X; Burris H; Petersen JA; Stanzel S; Strasak A; Patre M; Ellis P
    J Clin Oncol; 2017 Jan; 35(2):141-148. PubMed ID: 28056202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.